Singapore Selects Illumina for Major Genome Sequencing Programme Covering 450,000 People
Published
Singapore has chosen Illumina, a United States-based life sciences company, to take part in a national genome sequencing programme. The programme aims to sequence the genomes of about 450,000 people in the country.
Illumina makes sequencing and array technologies. These tools are used by researchers and healthcare providers to study the genetic information in human DNA. By reading this information, scientists can learn more about how genes affect health and disease.
The programme is expected to help doctors and researchers in Singapore understand genetic conditions better. Genome data can also support more personalised healthcare, where treatment is planned around a patient's own genetic profile. Details about the timeline and the cost of the programme were not included in the initial report.
The selection shows Singapore's continued investment in genomics and health research. Readers who want to know more about how the programme will work and how participants will be chosen should follow updates from the relevant government agencies and healthcare institutions.
Sources: Yahoo Finance Singapore
More Singapore news
- Singapore Needs More Tech Companies to Grow Its Stock Market, HSBC Strategist Says
- Singapore Tech Shares Rebound After Last Week's Sell-Off
- Databricks Plans to Double Its Singapore Team to 500 Staff
- Visa Sets Up Six Technology Hubs in New Singapore Centre
- US Congress Faces Possible Impeachment Fight Over Defence Secretary Pete Hegseth
- Giving Former Politicians Room to Return to Normal Life in Singapore
- Singapore Cloud Firm Megaspeed Faces Renewed US Scrutiny
- Iran Calls for Stronger Economic and Trade Ties with Singapore